629 related articles for article (PubMed ID: 21721597)
1. Elderly patients with community-acquired pneumonia: optimal treatment strategies.
Thiem U; Heppner HJ; Pientka L
Drugs Aging; 2011 Jul; 28(7):519-37. PubMed ID: 21721597
[TBL] [Abstract][Full Text] [Related]
2. [Guidelines for treatment of pneumonia in intensive care units].
Emmi V
Infez Med; 2005; Suppl():7-17. PubMed ID: 16801748
[TBL] [Abstract][Full Text] [Related]
3. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
4. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM
J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448
[TBL] [Abstract][Full Text] [Related]
5. New developments in antibacterial choice for lower respiratory tract infections in elderly patients.
Ferrara AM; Fietta AM
Drugs Aging; 2004; 21(3):167-86. PubMed ID: 14979735
[TBL] [Abstract][Full Text] [Related]
6. Current guidelines for the treatment of severe pneumonia and sepsis.
Bodmann KF
Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia.
Aspa J; Rajas O; de Castro FR
Expert Opin Pharmacother; 2008 Feb; 9(2):229-41. PubMed ID: 18201146
[TBL] [Abstract][Full Text] [Related]
8. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).
Mathai D; Lewis MT; Kugler KC; Pfaller MA; Jones RN;
Diagn Microbiol Infect Dis; 2001 Feb; 39(2):105-16. PubMed ID: 11248523
[TBL] [Abstract][Full Text] [Related]
11. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
[TBL] [Abstract][Full Text] [Related]
12. [Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012].
Zhao C; Zhang F; Wang Z; Cao B; Xu X; Sun H; Zhang R; Hu Y; Liu Z; Du Y; Chen R; Zhuo C; Su D; Liu Y; Hu B; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2015 Jan; 38(1):18-22. PubMed ID: 25791651
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
14. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
15. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
Pfaller MA; Ehrhardt AF; Jones RN
Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
[TBL] [Abstract][Full Text] [Related]
16. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
Gordon KA; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
19. Drug treatment of pneumococcal pneumonia in the elderly.
Neralla S; Meyer KC
Drugs Aging; 2004; 21(13):851-64. PubMed ID: 15493950
[TBL] [Abstract][Full Text] [Related]
20. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
